Skip to main content
OpenTrials

Clinical trial condition

Hemorrhagic Disorders

Explore clinical trials studying Hemorrhagic Disorders. Study availability and eligibility vary by location and protocol.

4,583 public trials 830 recruiting studies
Refine in advanced search Browse all conditions

Hemorrhagic Disorders trial results

Recruiting

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

NCT07105059

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Recruiting

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06574568

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Beijing Chao-yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Jishuitan Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Shunde Hospital of Southern Medical University Foshan, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View Trial Details
Recruiting

Fibrinogen Early In Severe Trauma StudY II

NCT05449834

Conditions
Cardiovascular Diseases, Coagulopathy, Haemorrhagic Shock, +12 more
Locations
  • John Hunter Hospital Newcastle, New South Wales, Australia
  • St Vincent's Hospital Sydney, New South Wales, Australia
  • Royal Prince Alfred Hospital Sydney, New South Wales, Australia
  • Royal North Shore Hospital Sydney, New South Wales, Australia
View all 24 locations
View Trial Details
Recruiting

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

NCT04414475

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University General Hospital of Patras Pátrai, Achaia, Greece
  • General Hospital of Athens "Alexandra" Attiki, Athens, Greece
  • General Hospital of Athens "Evangelismos" Athens, Attica, Greece
  • Theageneion Cancer Hospital Thessaloniki, Greece
View all 16 locations
View Trial Details
Recruiting

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

NCT06216158

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Universitätsklinikum Krems an der Donau Krems, Austria
  • Ordensklinikum Linz Elisabethinen Linz, Austria
  • Landeskrankenhaus Salzburg, Universitätsklinik für Innere Medizin III Salzburg, Austria
  • Klinik Ottakring Wien Vienna, Austria
View all 69 locations
View Trial Details

Related conditions